Radiation Oncology/RTOG Trials/9910

RTOG 99-10 (PROSTATE)

• Title: A Phase III Trial to Evaluate The Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate Risk Prostate Cancer
• Objective: To compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.
• Protocol:
  • Arm 1: TAS x 8 weeks followed by 70.2 Gy RT + concurrent TAS
  • Arm 2: TAS x 28 weeks followed by 70.2 Gy RT + concurrent TAS
• Eligibility:
  • (cT1b-T4 and GS 2-6 and PSA 10-100) or
  • (cT1b-T4 and GS 7 and PSA <20) or
  • (T1b-T1c and GS 8-10 and PSA <20)
  • N0M0
• Enrollment Target: 1540 patients
• Activation: February 14, 2000
• Closed: May 3, 2004